News
Genprex
GNPX · NASDAQ
$2.13+$0.05 (+2.40%)TodayMarket closed ·
Prev close $2.08
Latest news
- Press releasePRNewswire
Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Press releasePRNewswire
Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- Press releasePRNewswire
Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies
- Press releasePRNewswire
Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer
- Press releasePRNewswire
Genprex to Participate at BIO International Convention 2026
- Press releasePRNewswire
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting
- Press releasePRNewswire
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
- NewsAvi Kapoor
Top 3 Health Care Stocks That Are Set To Fly In Q2
- Press releasePRNewswire
Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
- Press releasePRNewswire
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
- Press releasePRNewswire
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting
- Press releasePRNewswire
Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy
- Press releasePRNewswire
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
- NewsChris Katje
Top Ranking Stock Picker From Congress Is Back Buying Small Cap Stocks Again: Here Are The Tickers
- Press releasePRNewswire
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
- Press releasePRNewswire
Genprex to Participate at BIO Europe Spring 2026
- NewsChris Katje
Congressman Who Bought Small-Cap Stocks In 2025 Is Back With New 2026 Pick: Here's What He's Buying
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- Press releasePRNewswire
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer
- Press releasePRNewswire
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
- Press releasePRNewswire
Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
- NewsChris Katje
Congressman Who Was Top 2025 Stock Picker Buys Shares Of $5M Company You've Never Heard Of
- Press releasePRNewswire
Genprex Provides Clinical Update on Diabetes Gene Therapy Program
- Press releasePRNewswire
Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies
- NewsChris Katje
Move Over, Pelosi: This Congress Member Posted 2025's Best Market Return With A 52% Gain
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- NewsChris Katje
Congressman Buys Shares Of Small Cap Lift Truck Company You've Probably Never Heard Of
- Press releasePRNewswire
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer
- Press releasePRNewswire
Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials
- Press releasePRNewswire
Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
- Press releasePRNewswire
Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Netflix Posts Downbeat Earnings, Joins Aveanna Healthcare, Texas Instruments And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsAvi Kapoor
Why J.B. Hunt Transport Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
- NewsAvi Kapoor
Gold Gains Over 1%; Abbott Shares Fall After Q3 Results
- NewsAvi Kapoor
S&P 500 Gains 1%; Bank of America Posts Upbeat Earnings
- NewsChris Katje
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.